Advertisement
Document › Details
ERS Genomics Ltd.. (1/13/20). "Press Release: ERS Genomics Licenses CRISPR Gene Editing Technology to Daiichi Sankyo to Support Internal Research and Development". Dublin.
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced the signing of a license agreement with Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan. The agreement provides Daiichi Sankyo with access to CRISPR/Cas9 genome editing technology intellectual property for use in its internal research and development.
ERS Genomics holds an exclusive worldwide license to the foundational intellectual property covering CRISPR/Cas9 for all applications other than use as a human therapeutic. Under the terms of the license, Daiichi Sankyo is able to use CRISPR technology to support its R&D initiatives to address areas of unmet medical need.
Eric Rhodes, CEO of ERS Genomics, said: “Daiichi Sankyo is our first large pharma licensee in Japan. CRISPR/Cas9 is revolutionary in genome editing; we look forward to observing how the company applies the technology to further advance its R&D operations.”
Financial details of the agreement are not disclosed.
About ERS Genomics
www.ersgenomics.com
ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.
Record changed: 2023-06-05 |
Advertisement
More documents for ERS Genomics Ltd.
- [1] ERS Genomics Ltd.. (3/26/24). "Press Release: Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration". Dublin....
- [2] ERS Genomics Ltd.. (3/13/24). "Press Release: Ricoh and ERS Genomics Enter into CRISPR/Cas9 License Agreement". Tokyo & Dublin....
- [3] Empyrean Neuroscience, Inc.. (10/18/22). "Press Release: Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders". New York, NY & Cambridge....
- [4] ERS Genomics Ltd.. (8/17/21). "Press Release: ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement". Dublin & Coralville, IA....
- [5] ERS Genomics Ltd.. (6/1/21). "Press Release: Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent and Allows Third". Dublin....
- [6] ERS Genomics Ltd.. (3/1/21). "Press Release: ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development". Dublin....
- [7] ERS Genomics Ltd.. (2/16/21). "Press Release: ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement". Dublin & Barcelona....
- [8] ERS Genomics Ltd.. (12/1/20). "Press Release: Vivlion GmbH Signs Worldwide License Agreement With ERS Genomics for CRISPR/Cas9 Patent Portfolio". Dublin & Frankfurt/M.....
- [9] ERS Genomics Ltd.. (9/22/20). "Press Release: ERS Genomics Appoints Michael Arciero as Vice-President of Intellectual Property & Commercial Development". Dublin....
- [10] ERS Genomics Ltd.. (9/14/20). "Press Release: ERS Genomics Provides Comment on US Patent Office Motions Decisions in CRISPR/Cas9 Interference Case". Dublin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top